A trial fibrillation (AF) is the most common cardiac arrhythmia in developed countries and increases the risks for stroke, heart failure, and death.
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Among cohorts of Asian patients with AF, the largest prospective AF cohort study in Japan was a subanalysis of A Multicenter Study on Warfarin Use and Optimal Anticoagulation Levels for Prevention of Cardiogenic Embolism in Japanese Patients With Atrial Fibrillation (J-RHYTHM Registry), which reported that the crude incidence of thromboembolic events was 2-fold higher in patients with permanent AF than in those with PAF; however, the difference disappeared after fully adjusting for potential confounding factors. 15 In accordance with the Western guidelines, current Japanese guidelines do not include the type of AF as a risk stratification factor. The aim of this study is to investigate the differences in baseline clinical characteristics and incidence of stroke/SE between PAF and persistent or permanent AF in the Registry Study of Atrial Fibrillation Patients in Fushimi-ku (Fushimi AF Registry), a community-based prospective survey of Japanese patients with AF.
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Methods
Study Cohort
The detailed study design, patient enrollment, the definition of the measurements, and subjects' baseline clinical characteristics of the Fushimi AF Registry were previously described (UMIN Clinical Trials Registry: UMIN000005834). 17 The inclusion criterion for the registry is the documentation of AF on a 12-lead ECG or Holter monitoring at any time. There are no exclusion criteria. The enrollment of patients was started in March 2011. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the ethical committees of the National Hospital Organization Kyoto Medical Center and Ijinkai Takeda General Hospital.
Type of AF and Data Definition
The definitions of the types of AF are as follows:
PAF: recurrent AF that terminates spontaneously and lasts ≤7 days; persistent AF: AF that lasts >7 days, which can be terminated by either pharmacological therapy or electric cardioversion; and permanent AF: AF that has been present for a long time, and pharmacological or electric cardioversion has not been performed, or one or several attempts have failed to restore sinus rhythm.
A patient was classified into 1 of the above-mentioned 3 clinical subtypes of AF at the time of enrollment based on their physician's diagnosis, using baseline ECG recordings and previous clinical history, including ascertainment of interval events during clinic visit as frequently as every 2 to 4 weeks. Because distinguishing persistent and permanent type is sometimes difficult in daily clinical practice, we combined these 2 subtypes as sustained AF (SAF) in this study, and compared baseline clinical characteristics and outcomes between PAF and SAF. The risk of stroke was evaluated by the CHADS 2 19 and the CHA 2 DS 2 -VASc scores. 20 CHADS 2 score is composed of congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and history of stroke. CHA 2 DS 2 -VASc score is composed of congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, history of stroke, vascular disease, age 65-74 years and female sex.
Study End Points
The primary end point in this analysis was the incidence of stroke/SE during follow-up period. Other clinical end points included the incidence of major bleeding, all-cause death, and composite end points of stroke, SE, and all-cause death during follow-up period. Stroke was defined as the sudden onset of a focal neurological deficit in a location consistent with the territory of a major cerebral artery, and the diagnosis of ischemic or hemorrhagic stroke was confirmed by computed tomography or magnetic resonance imaging. SE was defined as an acute vascular occlusion of an extremity or organ.
Statistical Analysis
Continuous variables are expressed as mean±SD or median and interquartile range. Categorical variables are presented as numbers and percentages. We compared categorical variables using the χ 2 test when appropriate; otherwise, we used Fisher exact test. We compared continuous variables using Student t test on the basis of the distribution. The Kaplan-Meier method was used to estimate the cumulative incidences of clinical events. We performed multivariate analysis using a Cox proportional hazards model. The covariates chosen to be included in the model 1 were PAF, components of the CHADS 2 risk score.
19 Those in the model 2 were the covariates included in the model 1, in addition to female sex and vascular disease, according to the components of the CHA 2 DS 2 -VASc risk score, 20 and low body weight. With regard to the latter, we have recently demonstrated that low body weight (≤50 kg) was independently associated with the incidence of stroke/SE in Japanese patients with AF. 21 We further A B C D Figure 1 . Distribution of age (A) and the CHA 2 DS 2 -VASc score (B) and rate of oral anticoagulants (OAC) prescription, according to age (C) and the CHA 2 DS 2 -VASc score (D). CHA 2 DS 2 -VASc score is composed of congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, history of stroke, vascular disease, age 65-74 years and female sex. PAF indicates paroxysmal atrial fibrillation; and SAF, sustained atrial fibrillation. 
Results
A total of 4115 patients were enrolled by the end of July 2014. Of 3666 patients who were enrolled 1 year before (by the end of July 2013), follow-up data (collected every year) were available for 3304 patients (follow-up rate, 90.1%). Among these 3304 patients, 1588 patients (48.1%) had PAF and 1716 (51.9%) had SAF. Median follow-up period was 746 days (interquartile range, 404-1109 days).
Baseline Clinical Characteristics
The baseline clinical characteristics of patients with PAF and SAF are summarized in Table 1 . Patients with PAF were younger and were more symptomatic. The most frequent symptom in both groups was palpitations. Patients with PAF were less likely to have a history of stroke/ SE, congestive heart failure, and chronic kidney disease. The CHADS 2 and CHA 2 DS 2 -VASc scores were lower in patients with PAF. There was a lower proportion of OAC use in PAF and the most common OAC used was warfarin because novel OAC use was limited when the majority of patients were enrolled. Figure 1 shows the distribution of patients with PAF and SAF according to age (A) and the CHA 2 DS 2 -VASc score (B) and the proportion of OAC prescription in PAF and SAF groups according to age (C) and the CHA 2 DS 2 -VASc score (D). Patients receiving OAC were less commonly seen in patients with PAF in all of the age, CHADS 2 score, or CHA 2 DS 2 -VASc score subpopulations.
Outcomes
The incidences of major clinical events in patients with or without OAC during the follow-up period are shown in Table 2 . During the follow-up period, progression from PAF to SAF occurred in 154 patients (9.7% of all patients with PAF). The annual incidence of stroke/SE was 1.4 and 3.0 per 100 person-years in patients without progression and those 
Multivariate Analyses
On multivariate analysis of the non-OAC users, after adjustment by the components of CHADS 2 score (model 1), PAF emerged as an independent risk factor for a reduced risk of stroke/SE (HR, 0.53; 95% CI, 0.31-0.89; P=0.02). Even after adjustment by the covariates included in model 2, PAF remained to be an independent risk fact or for a reduced risk of stroke/SE (HR, 0.51; 95% CI, 0.30-0.88; P=0.01; Table 3 ).
PAF remained to be an independent risk factor for a reduced risk of stroke/SE, when age was included in model 2 as a continuous variable (HR, 0.52; 95% CI, 0.31-0.89; P=0.02) or an ordinal variable of 4 age strata (<65, 65-74, 75-79, and ≥80 years; HR, 0.52; 95% CI, 0.31-0.88; P=0.01).
The nonadjusted HRs for PAF in 4 age strata were as follows: (1) 
Discussion
In the present study, we show that Asian patients with PAF have a lower incidence rate of stroke/SE than those with SAF. These differences were independently maintained even after adjustment for differences in baseline characteristics and were consistent whether on OAC or not taking OAC. This represents one of the largest community-based prospective cohorts of Asian patients with AF (specifically, Japanese patients with AF) to investigate the relationship between PAF and stroke risk when compared with patients with SAF.
Controversy About the Type of AF as a Stroke Risk
Previous randomized clinical studies 4, 5 and observational registry studies 6, 7 have suggested that patients with PAF have a risk of thromboembolic events similar to that in patients with SAF.
In contrast, other studies, including post hoc ancillary studies of large randomized clinical trials of OAC, have shown that the risk of stroke/SE was lower in anticoagulated patients with PAF than in those with SAF. 11, 12 In a large population 13 pattern of AF was a strong independent predictor of stroke risk and may be helpful to assess the risk/benefit for anticoagulant therapy, especially in lower risk patients.
In Japanese patients with AF, the J-RHYTHM Registry recently reported that the crude incidence of thromboembolic stroke was higher in permanent AF than in PAF, but the difference disappeared after adjusting for the well-established risk factors that were included in the CHA 2 DS 2 -VASc score. 15 Also, OAC and non-OAC users were not separately analyzed. The present study shows a significantly higher risk of stroke in patients with SAF, even after adjusting for those potential confounders and OAC use. This association is supported by the finding that the annual incidence of stroke/SE was lower in patients without AF progression than in patients who progressed to SAF. The discrepancy from the J-RHYTHM Registry may be because of the different inclusion criteria; 
AF Burden and Stroke Risk
Patients with PAF have a lower arrhythmia burden than those with SAF. One previous study showed that AF occurrences longer than 1 day were independently associated with embolic events in patients with implanted devices. 22 More recently, the SOS AF project, a pooled analysis of patients without permanent AF who were implanted with electronic devices, reported that the device-detected AF burden is associated with an increased risk of ischemic stroke. 23 Another study suggested that integration of AF presence/duration/burden had the potential to contribute to improved clinical risk stratification in patients with PAF. 24 Indeed, patients with PAF are more likely to receive rhythm-control therapies such as antiarrhythmic drugs or catheter ablation to maintain sinus rhythm, and this may reduce AF burden and the risk of stroke. However, the present study does not have data on AF burden by continuous monitoring.
Limitations
This study has several limitations. First, this is an observational study and provides only associative evidence, not causative. We cannot rule out the possibility of unmeasured or residual confounding, especially with age even after the multivariate analysis because advanced age and the type of AF were strongly associated. Second, antithrombotic drugs and doses were selected at the discretion of the attending physician. Third, we did not investigate the time in therapeutic range for patients taking warfarin during follow-up, and therefore it would be difficult to know how the quality of warfarin control influenced outcomes. Fourth, we were unable to assess AF burden, which might have affected the incidence of stroke/SE in patients with PAF. Fifth, the diagnosis of the type of AF was physician defined, in this real-world daily clinical practice study. This limitation would be intrinsic to most large multicenter registry studies. Also, patients with PAF may perhaps be more recently diagnosed and therefore at an earlier stage of AF, rather than having a different pattern of AF that was stable over time. Despite these limitations, our study clearly demonstrated that PAF was associated with lower risk of stroke/SE in Japanese patients with AF.
Conclusions
In this population-based cohort of Japanese patients with AF, PAF was independently associated with lower incidence of stroke/SE than SAF. This may aid decision making for anticoagulation, especially in patients with AF with few stroke risk factors.
